The impact of short-term ciclosporin A treatment on insulin secretion and insulin sensitivity in man

Nephrology Dialysis Transplantation

Volumn 22, Issue 6, 2007, Pages 1743-1749

  Hjelmesæth, Jøran ^a,d   Hagen, Liv Trine ^a   Åsberg, Anders ^a   Midtvedt, Karsten ^a   Størset, Øyvind ^b   Halvorsen, Carl Erik ^b   Mørkrid, Lars ^c   Hartmann, Anders ^a   Jenssen, Trond ^a,e  

^a UNIVERSITY OF OSLO   (Norway)

^b AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d VESTFOLD HOSPITAL TRUST   (Norway)

^e UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Ciclosporin A; Glucose clamp; Insulin resistance; Pancreatic cell function; Renal transplantation

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; VITAMIN D;

ADULT; AGED; ARTICLE; BODY WEIGHT; CAUCASIAN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLUCOSE CLAMP TECHNIQUE; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; NAUSEA; NORWAY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SHORT COURSE THERAPY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; CYCLOSPORINE; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 34447575023     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl820     Document Type: Article

References (41)

1. Markell M. New-onset diabetes mellitus in transplant patients: pathogenesis, complications and management. Am J Kidney Dis 2004; 43: 953-965
2. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC. Posttransplantation diabetes: A systematic review of the literature. Diabetes Care 2002; 25: 583-592
3. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178-185
4. Hjelmesæth J, Hartmann A, Kofstad J et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997; 64: 979-993
5. Ekstrand AV, Eriksson JG, Grönhagen-Riska C, Ahonen PJ, Groop LC. Insulin resistance and insulin deficiency in the pathogenesis of postransplant diabetes in man. Transplantation 1992; 53: 563-569
6. Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: A systematic review and meta-analysis. Am J Transplant 2004; 4: 583-595
7. van Duijnhoven EM, Boots JMM, Christiaans MHL, Wolffenbuttel BH, van Hooff JP. Influence of tacrolimus on glucose metabolism before and after renal transplantation: A prospective study. J Am Soc Nephrol 2001; 12: 583-588
8. Teutonico A, Schena PF, Di Paolo S. Glucose metabolism in renal transplant recipients: Effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005; 16: 3128-3135
9. Andrews RC, Walker BR. Glucocorticoids and insulin resistance: Old hormones, new targets. Clin Sci 1999; 96: 513-523
10. Henriksen JE, Alford F, Ward GM, Beck-Nielsen H. Risk and mechanism of dexamethasone deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients. Diabetologia 1997; 40: 1439-1448
11. Hjelmesæth J, Midtvedt K, Jenssen T, Hartmann A. Insulin resistance after renal transplantation; Impact of immunosuppressive and antihypertensive therapy. Diabetes Care 2001; 24: 2121-2126
12. Matsumoto K, Yamasaki H, Akazawa S et al. High-dose but not low-dose dexamethasone impairs glucose tolerance by inducing compensatory failure of pancreatic β-cells in normal men. J Clin Endocrinolo Metab 1996; 81: 2621-2626
13. Drachenberg CB, Klassen DK, Weir MR et al. Islet cell damage associated with tacrolimus and cyclosporine: Morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999; 68: 396-402
14. Nielsen JH, Mandrup-Poulsen T, Nerup J. Direct effects of cyclosporin A on human pancreatic beta-cells. Diabetes 1986; 35; 1049-1052
15. Andersson A, Borg H, Hallberg A. Hellerstrom C, Sandler S, Schnell A. Long-term effects of cyclosporin A on cultured mouse pancreatic islets. Diabetologia 1984; 27 [Suppl 1]: 66-69
16. Polastri L, Galbiati, F, Bertuzzi F et al. Secretory defects induced by immunosuppressive agents on human pancreatic beta-cells. Acta Diabetol 2002; 39: 229-233
17. Menegazzo LA, Ursich MJ, Fukui RT et al. Mechanism of the diabetogenic action of cyclosporin A. Horm Metab Res 1998; 30: 663-667
18. Fuhrer DK, Kobayashi M, Jiang H. Insulin release and suppression by tacrolimus, rapamycin and cyclosporin A are through regulation of the ATP-sensitive potassium channel. Diabetes Obes Metab 2001; 3: 393-402
19. Boots JM, van Duijnhoven EM, Christiaans MH, Wolffenbuttel BH, van Hooff JP. Glucose metabolism in renal transplant recipients on tacrolimus: The effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol 2002; 13: 221-227
20. Robertson RP, Franklin G, Nelson L. Intravenous glucose tolerance and pancreatic islet beta-cell function in patients with multiple sclerosis during 2-yr treatment with cyclosporin. Diabetes 1989; 38: 58-64
21. Caumo A, Luzi L. First-phase insulin secretion: Does it exist in real life? Considerations on shape and function. Am J Physiol Endocrinol Metab 2004; 287: E371-E378
22. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-E223
23. Mitrakou A, Vuorinen-Markkola H, Raptis G et al. Simultaneous assessment of insulin secretion and insulin sensitivity using a hyperglycemia clamp. J Clin Endocrinol Metab 1992; 75: 379-382
24. World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. J Am Med Assoc 1997; 277: 925-926
25. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003; 26: S5-S20
26. Midtvedt K, Hartmann A, Hjelmesæth J, Lund K, Bjerkely BL. Insulin resistance is a common denominator of posttransplant diabetes mellitus and impaired glucose tolerance in renal transplant recipients. Nephrol Dial Transplant 1998; 13: 427-431
27. Hume R. Prediction of lean body mass from height and weight. J Clin Pathol 1966; 19: 389-391
28. Natali A, Toschi E, Camastra A, Gastaldelli A, Groop L, Ferrannini E, on the behalf of the European Group for the Study of Insulin Resistance (EGIR). Determinants of post-absorptive endogenous glucose output in non-diabetic subjects. Diabetologia 2000; 43: 1266-1272
29. Altman DG. Practical statistics for medical research. Chapman & Hall London: 1991
30. Nam JH, Mun JI, Kim SI et al. beta-Cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus. Transplantation 2001. 71: 1417-1423
31. Sato T, Inagaki A, Uchida K et al. Diabetes mellitus after transplant: Relationship to pretransplant glucose metabolism and tacrolimus or cyclosporine A-based therapy. Transplantation 2003; 76: 1320-1326
32. Doyle ME, Egan JM. Pharmacological agents that directly modulate insulin secretion. Pharmacol Rev 2003; 55: 105-131
33. Oetjen E, Thoms KM, Laufer Y et al. The immunosuppressive drugs cyclosporin A and tacrolimus inhibit membrane depolarization-induced CREB transcriptional activity at the coactivator level. Br J Pharmacol 2005; 144: 982-993
34. Schwaninger M. Blume R, Oetjen E, Lux G, Knepel W. Inhibition of cAMP-responsive element-mediated gene transcription by cyclosporin A and FK506 after membrane depolarization. J Biol Chem 1993; 268: 23111-23115
35. Lawrence MC, Bhatt HS, Watterson JM, Easom RA, Regulation of insulin gene transcription by a Ca(2+)-responsive pathway involving calcineurin and nuclear factor of activated T cells. Mol Endocrinol 2001; 15: 1758-1767
36. Lawrence MC, Bhatt HS, Easom RA. NFAT regulates insulin gene promoter activity in response to synergistic pathways induced by glucose and glucagon-like peptide-1. Diabetes 2002; 51: 691-698
37. Bratanova-Tochkova TK, Cheng H, Daniel S et al. Triggering and augmentation mechanisms, granule pools, and biphasic insulin secretion. Diabetes 2002; 51. [Suppl 1]: S83-S90
38. Donelan MJ, Morfini G, Julyan R et al. Ca2+-dependent dephosphorylation of kinesin heavy chain on beta-granules in pancreatic beta-cells. Implications for regulated beta-granule transport and insulin exocytosis. J Biol Chem 2002; 277:24232-24242
39. Ebihara K, Fukunaga K, Matsumoto K, Shichiri M, Miyamoto E. Cyclosporin A stimulation of glucose-induced insulin secretion in MIN6 cells. Endocrinology 1996; 137:5255-5263
40. Konrad T, Steinmuller T, Vicini P et al. Regulation of glucose tolerance in patients after liver transplantation: Impact of cyclosporin versus tacrolimus therapy. Transplantation 2000; 69:2072-2078
41. Dresner LS, Andersen DK, Kahng KU, Munshi IA, Wait RB. Effects of cyclosporine on glucose metabolism. Surgery 1989; 106: 163-169